| 货号 | 45437S |
| 同种亚型 | Rabbit IgG |
| 反应种属 | Human |
| 应用 | WB,IP,IF,F |
| 目标/特异性 | NY-ESO-1 (D1Q2U) Rabbit mAb recognizes endogenous levels of total NY-ESO-1 protein. This antibody cross-reacts with NY-ESO-2/LAGE-1S. |
| 使用方法 | Western Blotting (1:1000) Immunoprecipitation (1:100) Immunofluorescence (Immunocytochemistry) (1:1600) Flow Cytometry (1:400) |
| 供应商 | CST |
| 灵敏度 | Endogenous |
| 背景 | Cancer/testis antigens (CTAs) are a family of more than 100 proteins whose normal expression is largely restricted to immune privileged germ cells of the testis, ovary, and trophoblast cells of the placenta. Although most normal somatic tissues are void of CTA expression, due to epigenetic silencing of gene expression, their expression is upregulated in a wide variety of human solid and liquid tumors (1,2). As such, CTAs have garnered much attention as attractive targets for a variety of immunotherapy-based approaches to selectively attack tumors (3). New York esophageal squamous cell carcinoma-1 (NY-ESO-1) is an X-linked CTA and was first identified by serological analysis of cDNA expression libraries in esophageal carcinoma (SEREX) (4,5). Like other CTAs, NY-ESO-1 expression is repressed in normal somatic tissues but becomes derepressed in a variety of human cancer types, such as multiple myeloma, non-small cell lung carcinoma, liposarcoma, and melanoma (6,7). Although the biological function of NY-ESO-1 remains enigmatic, its tumor-restricted expression pattern and high degree of immunogenicity have positioned it as a prominent target of immunotherapy-based strategies for tumor eradication (8). |
| 存放说明 | -20C |
| 计算分子量 | 20 (monomer), 40 (dimer) |
| 参考文献 | 1 . Caballero, O.L. and Chen, Y.T. (2009) Cancer Sci 100, 2014-21. 2 . De Smet, C. et al. (1999) Mol Cell Biol 19, 7327-35. 3 . Gjerstorff, M.F. et al. (2015) Oncotarget 6, 15772-87. 4 . Chen, Y.T. et al. (1997) Proc Natl Acad Sci U S A 94, 1914-8. 5 . Chen, Y.T. et al. (1997) Cytogenet Cell Genet 79, 237-40. 6 . Esfandiary, A. and Ghafouri-Fard, S. (2015) Immunotherapy 7, 411-39. 7 . Klar, A.S. et al. (2015) PLoS One 10, e0139221. 8 . Gnjatic, S. et al. (2006) Adv Cancer Res 95, 1-30. |
Western blot analysis of extracts from various cell lines using NY-ESO-1 (D1Q2U) Rabbit mAb (upper) and GAPDH (D16H11) XP® Rabbit mAb #5174 (lower). As expected, NY-ESO-1 protein is not detected in either HeLa cells or Jurkat cells. | |
Western blot analysis of extracts from 293T cells, mock transfected (-) or transfected with constructs expressing full-length human NY-ESO-1 (hNY-ESO-1; +) and full-length human NY-ESO-2/LAGE-1S (hNY-ESO-2; +), using NY-ESO-1 (D1Q2U) Rabbit mAb (upper) and GAPDH (D16H11) XP® Rabbit mAb #5174 (lower). | |
Immunoprecipitation of NY-ESO-1 from HT-1080 cell extracts. Lane 1 is 10% input, lane 2 is Rabbit (DA1E) mAb IgG XP® Isotype Control #3900, and lane3 is NY-ESO-1 (D1Q2U) Rabbit mAb. Anti-Rabbit HRP-conjugated light-chain-specific secondary antibody was used for detection. | |
Confocal immunofluorescent analysis of HT-1080 (left, positive) and HeLa (right, negative) cells using NY-ESO-1 (D1Q2U) Rabbit mAb (green). Blue pseudocolor = DRAQ5®#4084 (fluorescent DNA dye). | |
Flow cytometric analysis of Jurkat cells (blue) and U266 cells (green) using NY-ESO-1 (D1Q2U) Rabbit mAb. Anti-rabbit IgG (H+L), F(ab)2 Fragment (Alexa Fluor® 488 Conjugate) #4412 was used as a secondary antibody. |
